Skip to main content
PEPTARA LABS
Get Started

Research comparison

Retatrutide vs Ozempic: Full Comparison

Retatrutide vs Ozempic is a sourced comparison by Peptara Labs (peptaralabs.io) covering trial evidence, approval status, side effects and prices, with Wegovy shown separately. Retatrutide is an investigational molecule that acts on three receptors: GLP-1, GIP and glucagon. Ozempic is an approved brand of semaglutide, which acts on one of them, GLP-1.

Published by · Updated · How we research and check our pages

Educational information, not medical advice. Peptara Labs material is for research use only, not for human consumption. Retatrutide is not approved for use in people.[4] [15]

How do retatrutide and Ozempic compare side by side?

Retatrutide is an investigational molecule, while Ozempic is an approved semaglutide brand; the table separates both from Wegovy, another semaglutide brand. It compares identity, trial evidence, approval status, reported adverse events and prices. None of the weight figures is a published head-to-head result between retatrutide and semaglutide.[1] [2] [3] [4] [10]

On a phone, scroll the table horizontally to read all three product columns.

Retatrutide, Ozempic and Wegovy: sourced comparison, reviewed October 3, 2026
ComparisonRetatrutideOzempic (semaglutide)Wegovy (semaglutide)
Generic nameRetatrutide (LY3437943).[1]Semaglutide.[2]Semaglutide.[3]
DeveloperEli Lilly and Company.[1]Novo Nordisk.[2]Novo Nordisk.[3]
How it works (receptors)Agonist at GLP-1, GIP and glucagon receptors.[1]GLP-1 receptor agonist.[2]GLP-1 receptor agonist.[3]
US FDA status and dateNot FDA-approved as of October 3, 2026. Investigational; publication of phase 3 results is not approval.[4] [7]Injection first approved December 5, 2017. Ozempic tablets also have a US prescription label, posted August 19, 2026.[5] [11]First approved June 4, 2021. The current label adds a higher-dose Wegovy HD presentation and tablets.[6] [3]
What it is approved forNo approved indication. Not approved for use in people.[4]Injection: blood-glucose control in adults with type 2 diabetes, and cardiovascular and kidney risk indications in specified type 2 diabetes populations. No weight-management indication. Tablets have glucose-control and cardiovascular indications, not the injection's kidney indication.[2] [11]Weight management in eligible people with obesity or overweight. The original adult approval covered obesity, or overweight with a weight-related condition. Indications depend on formulation; the current label sets out the full scope.[6] [3]
Product formInvestigational; no approved product.[4]Injection pens and oral tablets, under separate labels.[2] [11]Injection pens and oral tablets, as described in the Wegovy label.[3]
Phase 3 weight resultTRIUMPH-1: -25.0% mean body weight in the highest dose group versus -3.9% with placebo at 80 weeks; 2,339 participants in the obesity trial. Treatment-regimen (intention-to-treat, ITT) estimand; NEJM, September 29, 2026.[7]SUSTAIN FORTE: -6.4 kg in the highest dose group versus -5.6 kg in the lower comparison group at 40 weeks; 961 adults with type 2 diabetes. Treatment-policy estimand; the between-group weight difference was not statistically significant. These are Ozempic label figures, not STEP-1 percentages.[2] [8]STEP-1: -14.9% versus -2.4% with placebo at 68 weeks; 1,961 adults with overweight or obesity and no diabetes. Treatment-policy estimand. Wegovy label Study 8: -18.8% in the highest dose group versus -3.9% with placebo at 72 weeks in adults with obesity. The Study 8 estimand is not specified in the verified label extract used here.[9] [3]
Phase 2 result (history)NEJM 2023 phase 2 trial: -24.2% mean body weight in the highest dose group versus -2.1% with placebo at 48 weeks; 338 adults with obesity or overweight and a weight-related condition. Historical result, separate from TRIUMPH-1. Estimand not specified in the verified abstract extract.[1]The Ozempic result selected above is from SUSTAIN FORTE, not a phase 2 comparison with retatrutide.[8]The Wegovy result selected above is from STEP-1, not a phase 2 comparison with retatrutide.[9]
Head-to-head trialsTRANSCEND-T2D-2 (NCT06260722) compares retatrutide with semaglutide in adults with type 2 diabetes. Results pending as of October 3, 2026; no published head-to-head result.[10]Semaglutide is the comparator in TRANSCEND-T2D-2. Primary completion was August 27, 2026, but the registry had no posted results at the October 3 check.[10]TRANSCEND-T2D-2 is a semaglutide comparison in type 2 diabetes. It is not a published retatrutide-versus-Wegovy obesity result.[10]
Common side effectsThe NEJM phase 2 trial reported gastrointestinal events most often, mostly mild to moderate, and heart-rate increases that peaked at 24 weeks then declined.[1]The injection label lists nausea, vomiting, diarrhea, abdominal pain and constipation as the most common adverse reactions, each reported in at least 5% of treated patients.[2]STEP-1 reported nausea and diarrhea as the most common adverse events. Gastrointestinal events led to discontinuation in 4.5% versus 0.8% with placebo.[9]
Boxed warningNo FDA-approved product label, so there is no approved boxed-warning comparison. This does not mean absence of risk.[4]Thyroid C-cell tumor risk, based on rodent findings; human relevance is unknown. The label contraindicates use with a personal or family history of medullary thyroid carcinoma or MEN 2.[2]Thyroid C-cell tumor risk, based on rodent findings; human relevance is unknown. See the Wegovy label for contraindications and other warnings.[3]
US list priceNo approved prescription product or established US prescription list price.[4]NovoCare displays $997.58 to $1,027.51 per pen: its phone and desktop blocks disagree. Both figures were verified October 3, 2026; this is not a self-pay quote.[13]NovoCare lists $1,349.02 per package, verified October 3, 2026. List price differs from self-pay program pricing.[14]
Vietnam registrationVietnam registration is not established by the sources cited here. Retatrutide is investigational; the FDA source addresses US status, not Vietnamese registration.[4]Pharmacity lists registration 570410174600 and marks Ozempic as prescription-required. The listing was verified October 3, 2026.[16]Vietnam registration not verified. The US Wegovy label does not establish registration in Vietnam, and Ozempic's registration cannot be applied to Wegovy.[3] [16]

The trials differ in population, length and estimand, so these numbers are not a head-to-head result. An estimand defines which treatment effects a trial estimates and how it handles events such as stopping treatment. The figures above are group means, not expected personal outcomes.

Share or cite this table

Add as preferred on Google

What is the difference between retatrutide and Ozempic?

The main differences are the molecule, receptor targets and approval status. Retatrutide is developed by Lilly and activates GLP-1, GIP and glucagon receptors. Ozempic contains Novo Nordisk's semaglutide, a GLP-1 receptor agonist. Ozempic injection was first FDA-approved on December 5, 2017; retatrutide remains unapproved as of October 3, 2026, despite published phase 3 findings.[1] [2] [5] [4] [7]

How much weight did people lose in the trials?

The named trials reported mean body-weight changes, not a prediction for any individual. TRIUMPH-1 reported -25.0% in retatrutide's highest dose group versus -3.9% with placebo at 80 weeks, using the treatment-regimen (ITT) estimand in 2,339 participants. SUSTAIN FORTE reported -6.4 kg in Ozempic's highest dose group versus -5.6 kg in the lower comparison group at 40 weeks in 961 adults with type 2 diabetes, using the treatment-policy estimand. STEP-1 reported -14.9% with semaglutide versus -2.4% with placebo at 68 weeks in 1,961 adults without diabetes, using the treatment-policy estimand. STEP-1 is the Wegovy evidence, not an Ozempic weight-management result. Retatrutide's earlier phase 2 trial reported -24.2% versus -2.1% with placebo at 48 weeks in 338 adults; that historical figure should not replace TRIUMPH-1.[7] [8] [2] [9] [1]

Is retatrutide the same as Ozempic?

No, retatrutide and Ozempic are different molecules. Ozempic is a brand of semaglutide. Retatrutide shares GLP-1 receptor activity with semaglutide but also activates GIP and glucagon receptors. So retatrutide is like Ozempic in one receptor target, but it is not Ozempic, a generic Ozempic product or an approved substitute.[1] [2] [4]

How does retatrutide compare with Wegovy?

Wegovy is the semaglutide brand with a weight-management indication, which makes its obesity trials relevant context, but they still do not prove how it compares directly with retatrutide. TRIUMPH-1 reported -25.0% mean body weight at 80 weeks in retatrutide's highest dose group using the treatment-regimen (ITT) estimand. STEP-1 reported -14.9% at 68 weeks with semaglutide using the treatment-policy estimand. The Wegovy label also reports Study 8 at 72 weeks: -18.8% in the highest dose group, -15.5% in the lower comparison group and -3.9% with placebo. The verified Study 8 extract does not name its estimand, so we do not treat it as a matched comparison with TRIUMPH-1. Wegovy has injection and tablet forms; these quoted weight results are from injection studies.[6] [7] [9] [3]

Is retatrutide stronger than Ozempic?

No published head-to-head result establishes that retatrutide is stronger or better than Ozempic. TRIUMPH-1 reported -25.0% mean body weight at 80 weeks with retatrutide in the highest dose group using the treatment-regimen (ITT) estimand. The Ozempic label reports SUSTAIN FORTE at -6.4 kg at 40 weeks in the highest dose group, using the treatment-policy estimand in adults with type 2 diabetes. The populations, duration and units differ, so ranking the drugs from those numbers would overstate the evidence. TRANSCEND-T2D-2 directly compares retatrutide with semaglutide in type 2 diabetes, but results were still pending on October 3, 2026.[7] [2] [8] [10]

Is retatrutide safer than Ozempic?

No published head-to-head result establishes that retatrutide is safer than Ozempic. Retatrutide's phase 2 trial reported mostly mild to moderate gastrointestinal events and heart-rate increases that peaked at 24 weeks before declining. The Ozempic label lists nausea, vomiting, diarrhea, abdominal pain and constipation as common adverse reactions, and carries a boxed warning about thyroid C-cell tumors based on rodent findings. STEP-1 reported gastrointestinal discontinuation in 4.5% with semaglutide versus 0.8% with placebo. Those separate observations do not establish relative risk. TRANSCEND-T2D-2 results are pending. Semaglutide also has cardiovascular trial reports from SUSTAIN-6 and SELECT, but neither is a retatrutide comparison.[1] [2] [9] [10] [18] [17]

Is retatrutide a substitute for Ozempic?

No. Retatrutide is not approved for use in people, and published trial findings do not make it a substitute for Ozempic or any other prescription product. Peptara Labs research material is not for human consumption, and Peptara Labs gives no medical or switching guidance. Approved treatment is a decision for a licensed physician.[4] [15]

Does Peptara Labs sell Ozempic or Wegovy?

No, Peptara Labs does not sell Ozempic or Wegovy. Ozempic and Wegovy are prescription semaglutide products, and the clinical findings on this page are not evidence of an outcome from Peptara Labs material.[15] [2] [3]

Is retatrutide FDA-approved?

No, retatrutide is not FDA-approved as of October 3, 2026. TRIUMPH-1 was published in NEJM on September 29, 2026, so describing all phase 3 results as unknown is out of date. A published trial and regulatory approval are separate events.[4] [7]

Are Ozempic and Wegovy the same thing?

Ozempic and Wegovy contain semaglutide, but they are different brands with different labeled indications and formulations. Ozempic's injection label concerns adults with type 2 diabetes and includes specified cardiovascular and kidney risk indications; it has no weight-management indication. Wegovy has a weight-management indication. Both now have tablet labels as well as injection labels, so a brand name alone does not identify the formulation or its full indications.[2] [3] [6] [11]

What side effects did the retatrutide and semaglutide trials report?

Gastrointestinal events were common in the retatrutide phase 2 trial and in STEP-1, while the Ozempic label lists nausea, vomiting, diarrhea, abdominal pain and constipation. Retatrutide's phase 2 trial also reported heart-rate increases peaking at 24 weeks. STEP-1 reported nausea and diarrhea as the most common adverse events and gastrointestinal discontinuation in 4.5% versus 0.8% with placebo. The semaglutide labels include a thyroid C-cell tumor boxed warning and warnings about pancreatitis and gallbladder events. This is a summary, not the complete adverse-event or warning list.[1] [9] [2] [3]

Is Ozempic registered in Vietnam?

Yes, the verified Pharmacity listing gives Ozempic registration number 570410174600 and marks it as prescription-required. It listed 4,745,000 VND per pen when checked on October 3, 2026. That listing does not establish Wegovy's registration, which we have not verified, or current pharmacy stock. We also do not have a verified Vietnam registration for retatrutide.[16]

How does Metsera compare with retatrutide?

We cannot give a sourced Metsera comparison from the evidence verified for this page. No Metsera trial findings were verified for this comparison, so we make no claim about relative weight change, adverse events or approval status.

Sources

Clinical and external price references were checked on October 3, 2026. Publication or label dates are shown below. Prices and program terms can change.

  1. Jastreboff et al. Retatrutide phase 2 obesity trial, NEJM. 2023. PMID 37366315; DOI 10.1056/NEJMoa2301972
  2. Novo Nordisk. Ozempic injection prescribing information, including SUSTAIN FORTE and boxed warning. Revised May 2026. Ozempic label; DailyMed label, posted June 10, 2026
  3. Novo Nordisk. Wegovy prescribing information, including Study 8 Table 12, forms and boxed warning. DailyMed version 19, posted June 30, 2026. Wegovy label; DailyMed label
  4. FDA. Concerns with unapproved GLP-1 drugs used for weight loss. October 1, 2026. FDA statement on unapproved retatrutide
  5. FDA. Ozempic original injection approval, NDA 209637. December 5, 2017. FDA approval letter
  6. FDA. Wegovy original approval, NDA 215256. June 4, 2021. Drugs@FDA approval record; Original Wegovy label
  7. TRIUMPH-1. Retatrutide phase 3 trial, NEJM. September 29, 2026, online publication. PMID 42814954; DOI 10.1056/NEJMoa2604169
  8. SUSTAIN FORTE. Semaglutide trial in type 2 diabetes, Lancet Diabetes & Endocrinology. July 21, 2021, online publication; September 2021 issue. PMID 34293304; DOI 10.1016/S2213-8587(21)00174-1
  9. Wilding et al. STEP-1 semaglutide trial, NEJM. 2021. PMID 33567185; DOI 10.1056/NEJMoa2032183
  10. ClinicalTrials.gov. TRANSCEND-T2D-2, retatrutide versus semaglutide in adults with type 2 diabetes. Record updated September 28, 2026; results pending at verification on October 3, 2026. NCT06260722; Registry data
  11. DailyMed. Ozempic and Rybelsus tablet prescribing information. Posted August 19, 2026. Tablet label
  12. NovoCare. US self-pay programs for Ozempic and Wegovy. Verified October 3, 2026; introductory offer ends December 31, 2026. NovoCare Pharmacy; Ozempic program terms
  13. NovoCare. Ozempic US list price; phone and desktop blocks display different figures. Verified October 3, 2026. Ozempic list price
  14. NovoCare. Wegovy US list price. Verified October 3, 2026. Wegovy list price
  15. Peptara Labs. Research-use-only Terms. Terms reviewed October 5, 2026. Research-use-only Terms
  16. Pharmacity. Vietnam Ozempic prescription listing and registration number. Verified October 3, 2026. Ozempic listing, registration 570410174600
  17. SELECT. Semaglutide cardiovascular outcomes trial, NEJM. December 14, 2023. PMID 37952131
  18. SUSTAIN-6. Semaglutide cardiovascular outcomes trial, NEJM. November 10, 2016. PMID 27633186
  19. SURMOUNT-1. Tirzepatide trial, NEJM; background for the sibling comparison. 2022. PMID 35658024

Related comparisons and research information

SURMOUNT-1 is the tirzepatide trial referenced for the related comparison; it is a separate study, not a retatrutide-versus-Ozempic result.[19]

A retatrutide calculator is published separately on peptidesvietnam.com.

Chat with us